Sunshine Biopharma (SBFM) Other Non-Current Assets (2017 - 2026)

Sunshine Biopharma's (SBFM) quarterly Other Non-Current Assets came in at $71740.0 in Q1 2026, up 845.19% on a QoQ basis from $7590.0 in Q4 2020.

Sunshine Biopharma (SBFM) Other Non-Current Assets (2017 - 2026) Analysis & Trends

Sunshine Biopharma (SBFM) has 5 years of Other Non-Current Assets data on file, last reported at $71740.0 in Q1 2026.

Quarterly Other Non-Current Assets changed N/A year-over-year to $71740.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71740.0 (changed N/A YoY) and the FY2020 annual result came in at $7590.0, changed 0.0% from the prior year.
Other Non-Current Assets improved to $71740.0 in Q1 2026, from $7590.0 in the prior quarter.
In the past five years, Other Non-Current Assets ranged from a high of $71740.0 in Q1 2026 to a low of $71740.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Other Non-Current Assets (Qtr)
1	Haleon	44.51 Bn	43.55 Bn	-	56.35 Mn
2	Teva Pharmaceutical Industries	43.52 Bn	39.86 Bn	2.15 Bn	1.79 Bn
3	Zoetis	32.43 Bn	30.75 Bn	1.05 Bn	384.00 Mn
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	503.80 Mn
5	United Therapeutics	21.87 Bn	19.21 Bn	683.80 Mn	239.50 Mn
6	Viatris	18.98 Bn	18.09 Bn	1.46 Bn	1.06 Bn
7	Neurocrine Biosciences	15.43 Bn	15.04 Bn	935.80 Mn	59.30 Mn
8	Elanco Animal Health	12.02 Bn	11.49 Bn	798.00 Mn	304.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	13.00 Mn
10	Sunshine Biopharma	1.60 Mn	-12.15 Mn	2.43 Mn	281,480.00

Download Data